Moreau E J, Matutes E, A'Hern R P, Morilla A M, Morilla R M, Owusu-Ankomah K A, Seon B K, Catovsky D
Academic Department of Haematology and Cytogenetics, Royal Marsden Hospital, London, England.
Am J Clin Pathol. 1997 Oct;108(4):378-82. doi: 10.1093/ajcp/108.4.378.
A scoring system, based on the immunophenotypic analysis of a panel of five membrane markers (CD5, CD22, CD23, FMC7, SmIg) was shown to be useful in the distinction between chronic lymphocytic leukemia (CLL) and other B-cell lymphoproliferative diseases (non-CLL). We investigated whether the monoclonal antibody SN8 (CD79b) could improve our previous scoring system. Peripheral blood samples of 298 patients with CLL and 166 patients with non-CLL were analyzed by flow cytometry. Using the five standard markers, the accuracy of the scoring system was 91.8%, using a cutoff of 4 points or higher, to distinguish CLL from non-CLL. This was increased to 96.6% if SN8 was added and a cutoff of 4 points or higher was also used. A similar accuracy, 96.8%, was observed if CD22 was excluded and a cutoff of 3 points or higher was used. Thus, the replacement of CD22 by SN8 in the original scoring system significantly increases its potential to discriminate between CLL and other B-cell lymphoproliferative diseases.
一种基于对一组五个膜标志物（CD5、CD22、CD23、FMC7、Smlg）进行免疫表型分析的评分系统，已被证明有助于区分慢性淋巴细胞白血病（CLL）和其他B细胞淋巴增殖性疾病（非CLL）。我们研究了单克隆抗体SN8（CD79b）是否能改进我们之前的评分系统。通过流式细胞术分析了298例CLL患者和166例非CLL患者的外周血样本。使用五个标准标志物时，评分系统区分CLL与非CLL的准确性为91.8%，截断值为4分或更高。如果加入SN8且截断值也为4分或更高，这一准确性提高到了96.6%。如果排除CD22且截断值为3分或更高，则观察到类似的准确性，即96.8%。因此，在原始评分系统中用SN8替代CD22可显著提高其区分CLL和其他B细胞淋巴增殖性疾病的能力。
